These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31655410)

  • 1. Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®).
    Pons L; Vilain C; Volteau M; Picaut P
    J Neurol Sci; 2019 Dec; 407():116516. PubMed ID: 31655410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
    Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
    Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.
    Marciniak C; McAllister P; Walker H; Brashear A; Edgley S; Deltombe T; Khatkova S; Banach M; Gul F; Vilain C; Picaut P; Grandoulier AS; Gracies JM;
    PM R; 2017 Dec; 9(12):1181-1190. PubMed ID: 28625615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.
    Wohlfarth K; Schwandt I; Wegner F; Jürgens T; Gelbrich G; Wagner A; Bogdahn U; Schulte-Mattler W
    J Neurol; 2008 Dec; 255(12):1932-9. PubMed ID: 18854916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
    Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.
    Lew MF; Brashear A; Dashtipour K; Isaacson S; Hauser RA; Maisonobe P; Snyder D; Ondo W
    Int J Neurosci; 2018 Jul; 128(7):619-626. PubMed ID: 29343142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
    Gracies JM; Esquenazi A; Brashear A; Banach M; Kocer S; Jech R; Khatkova S; Benetin J; Vecchio M; McAllister P; Ilkowski J; Ochudlo S; Catus F; Grandoulier AS; Vilain C; Picaut P;
    Neurology; 2017 Nov; 89(22):2245-2253. PubMed ID: 29093068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.
    Ascher B; Kestemont P; Boineau D; Bodokh I; Stein A; Heckmann M; Dendorfer M; Pavicic T; Volteau M; Tse A; Picaut P; Rzany B
    Aesthet Surg J; 2018 Feb; 38(2):183-191. PubMed ID: 28200002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study.
    Mordin M; Masaquel C; Abbott C; Copley-Merriman C
    BMJ Open; 2014 Oct; 4(10):e005150. PubMed ID: 25324317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.
    Nestor M; Ablon G; Pickett A
    Aesthet Surg J; 2017 May; 37(suppl_1):S20-S31. PubMed ID: 28388717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study.
    Yoelin SG; Dhawan SS; Vitarella D; Ahmad W; Hasan F; Abushakra S
    Plast Reconstr Surg; 2018 Dec; 142(6):847e-855e. PubMed ID: 30489516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AbobotulinumtoxinA Efficacy and Safety in Children With Equinus Foot Previously Treated With Botulinum Toxin.
    Dabrowski E; Bonikowski M; Gormley M; Volteau M; Picaut P; Delgado MR
    Pediatr Neurol; 2018 May; 82():44-49. PubMed ID: 29625849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.
    Elliott M; Maignel J; Liu SM; Favre-Guilmard C; Mir I; Farrow P; Hornby F; Marlin S; Palan S; Beard M; Krupp J
    PLoS One; 2017; 12(10):e0185628. PubMed ID: 28982136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
    Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
    Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical duration of action of different botulinum toxin types in humans.
    Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
    Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
    Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
    Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report.
    Hefter H; Beek J; Rosenthal D; Samadzadeh S
    Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34203875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain Reduction With AbobotulinumtoxinA for the Treatment of Hallux Valgus in Adult Participants: Results of a Randomized and Placebo-Controlled Phase 2 Trial.
    Armstrong DG; DiDomenico LA; Baravarian B; Parekh SG; Volteau M; Silva R
    J Foot Ankle Surg; 2023; 62(2):244-253. PubMed ID: 36335048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.